Main Products

Chugai’s prescribed medicines are categorized into oncology and primary (excl. oncology).
View details in a PDF format.

Chugai Main Products PDF [PDF 496KB]

Oncology Area

Alecensa® (alectinib) ALK inhibitor
Avastin® (bevacizumab) Anti-VEGF humanized monoclonal antibody
FoundationOne® CDx Cancer Genomic Profile
FoundationOne® Liquid CDx Cancer Genomic Profile
-
Gazyva® (obinutuzumab) Glycoengineered type II anti-CD20 monoclonal antibody
Herceptin® (trastuzumab) Anti-HER2 humanized monoclonal antibody
Kadcyla® (trastuzumab emtansine) Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
Perjeta® (pertuzumab) HER2 dimerization inhibitory humanized monoclonal antibody
Polivy® (polatuzumab vedotin) Anti-CD79b antibody-drug conjugate
Rituxan® (rituximab) Anti-CD20 monoclonal antibody
Rozlytrek® (entrectinib) ROS1/TRK inhibitor
Tecentriq® (atezolizumab) Engineered anti-PD-L1 monoclonal antibody
Xeloda® (capecitabine) Antimetabolite, 5-FU derivative

Primary Area (excl. Oncology)

Actemra® (tocilizumab) Humanized anti-human IL-6 receptor monoclonal antibody
Bonviva® (ibandronate) Bisphosphonate anti-resorptive agent
CellCept® (mycophenolate mofetil) Immunosuppressant
Edirol® (eldecalcitol) Active vitamin D3 derivative
Enspryng® (satralizumab) pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody
Evrysdi® (risdiplam) SMN2 splicing modifier
Hemlibra® (emicizumab) Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody
Mircera® (epoetin beta pegol) Long-acting erythropoiesis-stimulating agent
Oxarol® (maxacalcitol) Agent for secondary hyperparathyroidism
Ronapreve® (casirivimab/imdevimab) Anti-SARS-CoV-2 monoclonal antibody
Tamiflu® (oseltamivir) Anti-influenza agent
  • Like
  • Tweet
  • LINE it!
  • E-mail

Main Products / Development Pipeline

Back to top